Online wellness clinics in Australia exploit regulatory gaps to supply unapproved peptides and anti-aging injections by using compounding exemptions and special access pathways designed for legitimate medical need. These substances lack human evidence for their claimed effects and carry undisclosed risks that bypass safety evaluation.
Key Points
- Unapproved peptides marketed for anti-aging lack efficacy evidence in humans
- Clinics circumvent regulation through compounding exemptions meant for individual patients
- Regulatory gap between TGA and Ahpra enables supply without safety assessment
Longevity Analysis
The absence of safety evaluation creates fundamental uncertainty about how these substances affect the body's core functions—energy production, hormonal regulation, regeneration, and defense. Practitioners prescribing these compounds after minimal assessment cannot decode what signal they're addressing or what interference they're creating. Without regulatory oversight of manufacturing, dosing, purity, and long-term effects, individuals cannot execute informed practice. The regulatory framework fails to distinguish between legitimate therapeutic need and commercial exploitation of longevity-seeking patients, shifting responsibility entirely to individual discernment without adequate data.
Original published by The Conversation - Longevity, by Christopher Rudge, Lecturer in Law, Sydney Law School, University of Sydney.